InsiderSignalSign in

← Insider buys

RVMD

Revolution Medicines, Inc. · Healthcare

Insiders sold $142.6M of Revolution Medicines, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$142.6MSold, 12 mo

$40.1BMarket cap

RVMD over the last year

No insider buys filed in this year

RVMD after insider buys

3 months after each buy, from the first price a copier could get.

−12.9%Average

−6.4 ptsVs S&P 500

2 of 10Higher

10 buys since 2020 with 3 months of prices.

Every filing

180 insider filings since 2020, newest first

Alan B. Sandler · Chief Development Officer

$1.3M−10.7%Oct 1

Jeff Cislini · SVP and General Counsel

$159K−1.5%Sep 29

Anthony Mancini · Insider

$743K−8.5%Sep 28

Elizabeth M Anderson · Director

$2.0M−70.1%Sep 24

Anthony Mancini · Insider

$347K−4.2%Sep 22

Alan B. Sandler · Chief Development Officer

$68K−0.6%Sep 18

Anthony Mancini · Insider

$353K−4.0%Sep 18

Stephen Michael Kelsey · Insider

$1.1M−1.9%Sep 18

Margaret A Horn · Chief Operating Officer

$990K−3.2%Sep 18

Mark A Goldsmith · Insider

$2.8M−5.2%Sep 18

Jeff Cislini · SVP and General Counsel

$671K−6.0%Sep 18

Jack Anders · Chief Financial Officer

$808K−3.3%Sep 18

Stephen Michael Kelsey · Insider

$18.7M−24.1%Sep 15

Anthony Mancini · Insider

$3.2M−26.0%Sep 14

Lorence H. Kim · Director

$3.6M−100.0%Sep 10

Lorence H. Kim · Director

$11.4M−76.6%Sep 2

Jeff Cislini · General Counsel

$11.9M−50.4%Aug 25

Mark A Goldsmith · Insider

$18.0M−58.3%Aug 25

Sushil Patel · Director

$1.0M−20.5%Jul 1

Jack Anders · Chief Financial Officer

$3.4M−14.0%Jun 26

Anthony Mancini · Insider

$720K−8.5%Jun 18

Mark A Goldsmith · Insider

$1.6M−3.6%Jun 18

Jeff Cislini · General Counsel

$337K−3.7%Jun 18

Jack Anders · Chief Financial Officer

$425K−2.2%Jun 18

Stephen Michael Kelsey · Insider

$652K−1.4%Jun 18

Margaret A Horn · Chief Operating Officer

$15.0M−37.7%Jun 17

Anthony Mancini · Insider

$481K−5.4%May 28

Mark A Goldsmith · Insider

$18.0M−11.0%Apr 17

Mark A Goldsmith · Insider

$1.3M−1.0%Mar 19

Lin Wei · Chief Medical Officer

$206K−2.0%Mar 19

Stephen Michael Kelsey · Insider

$428K−1.0%Mar 19

Margaret A Horn · COO

$456K−3.0%Mar 19

Jack Anders · CFO

$274K−2.0%Mar 19

Jeff Cislini · General Counsel

$292K−5.0%Mar 19

Mark A Goldsmith · Insider

$3.6M−4.0%Mar 3

Jeff Cislini · General Counsel

$105K−2.0%Jan 23

Margaret A Horn · COO

$7.5M−35.0%Jan 9

Jack Anders · CFO

$980K−8.0%Jan 9

Mark A Goldsmith · Insider

$1.2M−2.0%Dec 18

Jeff Cislini · General Counsel

$206K−5.0%Dec 18

Stephen Michael Kelsey · Insider

$418K−2.0%Dec 18

Margaret A Horn · COO

$372K−3.0%Dec 18

Jack Anders · CFO

$239K−3.0%Dec 18

Mark A Goldsmith · Insider

$5.0M−7.0%Nov 26

Jack Anders · CFO

$401K−5.0%Nov 26

Thilo Schroeder · Director

$60.0M+21.0%Dec 9

Jeff Cislini · General Counsel

$141K−6.0%Nov 19

Stephen Michael Kelsey · Insider

$978K−6.0%Nov 15

Jeff Cislini · General Counsel

$360K−12.0%Nov 8

Mark A Goldsmith · Insider

$3.9M−8.0%Nov 5

About Revolution Medicines, Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.